Manulife Singapore has introduced two industry-first collaborations that offer best-in-class health screenings, aimed at enhancing the quality of life for its customers as they approach their golden years.
These industry initiatives further emphasise Manulife’s commitment to better serve its customers, setting new benchmarks for personalised health solutions as Singapore approaches "super-aged" status by 2026 and the widening gap between life span and health span has become a pertinent issue for Singaporeans.
- Revolutionising cancer care with Guardant Health
This new initiative will allow customers with advanced solid tumour cancers better access to timely and tailored cancer care, using the Guardant360® liquid biopsy test.
Benefits include:
- Comprehensive genomic profiling across all solid cancers from a simple blood draw;
- Results within seven days to guide personalised treatment decisions; and
- A solution for patients who lack sufficient tumour tissue for standard tissue biopsies.
“We are committed to offering solutions that not only protect our customers financially but also help them navigate their health journeys,” said Mr Harshal Shah, Chief Marketing Officer, Asia, at Manulife. This collaboration reflects our mission of helping our customers make easier decisions and live better lives, even during the most challenging health conditions.”
“We are excited to partner with Manulife and provide improved access to our liquid biopsy technology in Singapore. For a patient with an advanced solid tumour cancer, time to appropriate treatment is key. Our commitment remains to improve patient outcomes by helping oncologists match patients to the right targeted treatment quickly,” said Mr Simran Singh, CEO at Guardant Health AMEA.
- First-in-Asia gut microbiome screening with AMILI
In another industry-first initiative, Manulife’s collaboration with AMILI will introduce advanced gut microbiome screening for its customers.
Key highlights include better access to:
- Precise gut health insights based on Asia’s largest multi-ethnic microbiome database;
- Tailored food and nutrition recommendations to enhance immunity, brain health, and overall well-being; and
- Complimentary consultations with AMILI’s experts to empower actionable health improvements.
“This collaboration with AMILI exemplifies how we are combining innovation with personalised care, empowering our financial consultants to offer solutions that go beyond financial protection and truly enhance health outcomes for our customers. By providing access to such advanced technology, we are reinforcing our commitment to our customers' long-term health and wellness,” said Dr Khoo Kah Siang, CEO of Manulife Singapore.
“’Good health begins with gut health’ as the saying goes. We see incredible potential in what the Singapore health minister describes as “predictive preventive care”, to improve lives by personalising health insights based on the gut microbiome and other data,” said Dr Jeremy Lim, CEO and co-founder of AMILI.